Pictet Asset Management Holding SA decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 22.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 588,009 shares of the biopharmaceutical company’s stock after selling 165,686 shares during the period. Pictet Asset Management Holding SA’s holdings in Ultragenyx Pharmaceutical were worth $9,004,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Assenagon Asset Management S.A. grew its holdings in Ultragenyx Pharmaceutical by 295.4% during the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock worth $7,182,000 after acquiring an additional 357,005 shares during the period. BlackRock Inc. bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth about $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth about $6,397,000. Deutsche Bank AG bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth about $5,503,000. Finally, Corient Private Wealth LP acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $4,644,000. Institutional investors own 97.67% of the company’s stock.
Ultragenyx Pharmaceutical Price Performance
Shares of NASDAQ RARE opened at $16.08 on Monday. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -3.10 and a beta of 0.37. The stock’s fifty day simple moving average is $15.29 and its 200 day simple moving average is $22.52. Ultragenyx Pharmaceutical Inc. has a 52-week low of $12.73 and a 52-week high of $39.89.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. During the same quarter in the previous year, the business earned ($1.81) earnings per share. The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.21 earnings per share for the current year.
Insider Buying and Selling at Ultragenyx Pharmaceutical
In related news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. This trade represents a 7.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 8,510 shares of company stock valued at $127,561. Company insiders own 5.20% of the company’s stock.
Wall Street Analyst Weigh In
RARE has been the subject of several research reports. Robert W. Baird lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $40.00 to $16.00 in a research report on Thursday, September 3rd. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price on the stock. in a report on Thursday, September 3rd. UBS Group started coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday, October 15th. They set a “neutral” rating and a $16.00 target price for the company. Finally, William Blair upgraded shares of Ultragenyx Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $29.79.
Check Out Our Latest Stock Analysis on RARE
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
Further Reading
- Five stocks we like better than Ultragenyx Pharmaceutical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
